TARA

Protara Therapeutics, Inc.

4 filings tracked

healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bearishMay 13

Operating losses widened to $19.6 million as R&D and G&A expenses increased year-over-year.

margin compression

60%

bullishMay 13

Clinical milestones triggered a warrant exercise window potentially providing $51.2 million in proceeds.

capital raise

70%

bullishMay 13

TARA-002 achieved a 68% CR rate, significantly exceeding the FDA's 41.9% efficacy hurdle.

guidance raise

80%

bullishMay 13

Management claims disciplined capital allocation and operational progress in Q1 results.

earnings beat

60%

bearishMay 13

Opaque financial reporting and lack of cash disclosure suggest potential for imminent financing.

dilution risk

70%

neutralMay 13

Concerns regarding the management of 2027 convertible notes.

debt restructure

50%

bearishMay 13

Operating losses widened to $19.6 million as R&D and G&A expenses increased year-over-year.

margin compression

60%

bullishMay 13

Clinical milestones triggered a warrant exercise window potentially providing $51.2 million in proceeds.

capital raise

70%

bullishMay 13

TARA-002 achieved a 68% CR rate, significantly exceeding the FDA's 41.9% efficacy hurdle.

guidance raise

80%

bullishMay 13

Management claims disciplined capital allocation and operational progress in Q1 results.

earnings beat

60%

bearishMay 13

Opaque financial reporting and lack of cash disclosure suggest potential for imminent financing.

dilution risk

70%

neutralMay 13

Concerns regarding the management of 2027 convertible notes.

debt restructure

50%

Filing History

10-QMay 13, 2026

The Q1 2026 filing presents a classic biotech trade-off between high-conviction clinical data and intensifying capital consumption. On one hand, the TARA-002 data is objectively impressive, providing a clear regulatory path and a potential liquidity event via warrant exercises. On the other hand, the acceleration in quarterly cash burn and the small sample size of the current data set introduce a layer of execution risk that cannot be ignored. Investors are now weighing the probability of a successful BLA submission for lymphatic malformations and the outcome of the ADVANCED-3 bladder cancer trial against a backdrop of increasing operational costs. The company's ability to convert its current clinical momentum into a sustainable financial footing—without excessive dilution—will be the primary driver of valuation in the coming year.

8-KMay 13, 2026

The filing presents a stark contrast between management's narrative of strategic scaling and the market's concern over transparency. While the company claims to be de-risking its path to value-inflection events, the lean nature of the 8-K disclosure leaves significant questions regarding the actual cash runway and debt obligations. Investors are left to weigh the promise of clinical advancement against the red flags of opaque financial reporting and potential leadership instability.